Cargando…
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity
BACKGROUND: Signal regulatory protein α (SIRPα) is a myeloid-lineage inhibitory receptor that restricts innate immunity through engagement of its cell surface ligand CD47. Blockade of the CD47–SIRPα interaction synergizes with tumor-specific antibodies and T-cell checkpoint inhibitors by promoting m...
Autores principales: | Kuo, Tracy C., Chen, Amy, Harrabi, Ons, Sockolosky, Jonathan T., Zhang, Anli, Sangalang, Emma, Doyle, Laura V., Kauder, Steven E., Fontaine, Danielle, Bollini, Sangeetha, Han, Bora, Fu, Yang-Xin, Sim, Janet, Pons, Jaume, Wan, Hong I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706287/ https://www.ncbi.nlm.nih.gov/pubmed/33256806 http://dx.doi.org/10.1186/s13045-020-00989-w |
Ejemplares similares
-
Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα
por: Sim, Janet, et al.
Publicado: (2019) -
ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile
por: Kauder, Steven E., et al.
Publicado: (2018) -
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020) -
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
por: Voets, Erik, et al.
Publicado: (2019) -
Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
por: Behrens, Leonie M., et al.
Publicado: (2022)